{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:56:06Z","timestamp":1791107766293,"version":"4.1.0"},"reference-count":53,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1254\/jphs.fp0060801","type":"journal-article","created":{"date-parts":[[2006,11,20]],"date-time":"2006-11-20T05:46:08Z","timestamp":1164001568000},"page":"288-295","source":"Crossref","is-referenced-by-count":22,"title":["Aldosterone Synthesis and Cytokine Production in Human Peripheral Blood Mononuclear Cells"],"prefix":"10.1254","volume":"102","author":[{"given":"Ryuzea","family":"Miura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kajiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Fukushima Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Emori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–126.","DOI":"10.1056\/NEJM199901143400207"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002;144:S2–S7.","DOI":"10.1067\/mhj.2002.129969"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.11.037"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000021412.56621.A2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182–1191.","DOI":"10.1161\/01.RES.83.12.1182"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 1998;98:794–799.","DOI":"10.1161\/01.CIR.98.8.794"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068340.96506.0F"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213–2220.","DOI":"10.1161\/01.CIR.0000127949.05756.9D"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2785"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Oberleithner H, Ludwig T, Riethmuller C, Hillebrand U, Albermann L, Schafer C, et al. Human endothelium: target for aldosterone. Hypertension. 2004;43:952–956.","DOI":"10.1161\/01.HYP.0000123572.45556.a5"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)00531-1"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(98)00103-2"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000102404.81461.25"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37:787–793.","DOI":"10.1161\/01.HYP.37.2.787"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773–1781.","DOI":"10.1016\/S0002-9440(10)64454-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–1064.","DOI":"10.1161\/01.CIR.100.10.1056"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.","DOI":"10.1056\/NEJMoa010713"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457–465.","DOI":"10.1677\/joe.0.0910457"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091234.45664.62"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Folkeringa RJ, Pinto YM, Crijns HJ. Aldosterone levels after angiotensin receptor blocker treatment. Circulation. 2004;109: e182; author reply e182.","DOI":"10.1161\/01.CIR.0000124885.70372.41"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.SC0060049"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem (Tokyo). 1978;84:1013–1015.","DOI":"10.1093\/oxfordjournals.jbchem.a132183"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917040-00012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol. 1985;248:E388–E390.","DOI":"10.1152\/ajpendo.1985.248.3.E388"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.49.31092"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00264-8"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(02)00041-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation. 1997;95:1201–1206.","DOI":"10.1161\/01.CIR.95.5.1201"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2003.07.006"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.7.2519"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.11.5121"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.5.1633"},{"key":"35","unstructured":"35 Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, et al. Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept. 2006;134:69–74.","DOI":"10.1016\/j.regpep.2006.01.007"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Fukuda N, Nakayama M, Jian T, Satoh C, Nakayama T, Soma M, et al. Leukocyte angiotensin II levels inpatients with essential hypertension:relation to insulin resistance. Am J Hypertens. 2003;16:129–134.","DOI":"10.1016\/S0895-7061(02)03145-X"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72–77.","DOI":"10.1161\/01.CIR.103.1.72"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.2797"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1210\/en.138.8.3369"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Pitt B. A new HOPE for aldosterone blockade? Circulation. 2004;110:1714–1716.","DOI":"10.1161\/01.CIR.0000144399.60132.3D"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–597.","DOI":"10.1161\/01.CIR.101.6.594"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1210\/me.10.12.1549"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000096609.73772.C5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res. 2004;62:460–467.","DOI":"10.1016\/j.cardiores.2004.01.011"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Keidar S, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis. 1999;146:249–257.","DOI":"10.1016\/S0021-9150(99)00145-8"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.34.21609"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol. 2005;78:195–201.","DOI":"10.1189\/jlb.1204715"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 1997;81:804–811.","DOI":"10.1161\/01.RES.81.5.804"},{"key":"50","unstructured":"50 Zoja C, Wang JM, Bettoni S, Sironi M, Renzi D, Chiaffarino F, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol. 1991;138:991–1003."},{"issue":"4","key":"51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","volume":"33","author":"ROBERT V","year":"1999","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000140771.21243.ed"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension. 2004;44:751–757.","DOI":"10.1161\/01.HYP.0000144466.11568.7e"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:15:54Z","timestamp":1621437354000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/102\/3\/102_3_288\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.fp0060801","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}